Treace Medical Concepts (TMCI)
(Delayed Data from NSDQ)
$6.18 USD
+0.20 (3.34%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $6.18 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
TMCI 6.18 +0.20(3.34%)
Will TMCI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TMCI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TMCI
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2
TMCI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Tops Revenue Estimates
PROCEPT BioRobotics Corporation (PRCT) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates
Other News for TMCI
H&R Block Posts Upbeat Earnings, Joins Alibaba Group, CI&T And Other Big Stocks Moving Higher On Friday
Invesco Health Care Fund Q2 2024 Review
Commit To Buy Treace Medical Concepts At $5, Earn 21.2% Annualized Using Options
Morgan Stanley Keeps Their Hold Rating on Treace Medical Concepts (TMCI)
Truist Financial Sticks to Their Hold Rating for Treace Medical Concepts (TMCI)